Sorafenib cardiotoxicity increases mortality after myocardial infarction. - Wikidata - awgldk - TriplyDB

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

http://www.wikidata.org/entity/Q33681995

about

Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities Stem cell therapy and breast cancer treatment: review of stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer treatment.Heme oxygenase-1 regulates mitochondrial quality control in the heart.Chemotherapy-induced cardiomyopathy.SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa i Myocardial apoptosis in heart disease: does the emperor have clothes?Acute Catecholamine Exposure Causes Reversible Myocyte Injury Without Cardiac Regeneration.Doxorubicin upregulates CXCR4 via miR-200c/ZEB1-dependent mechanism in human cardiac mesenchymal progenitor cells.Hydrogen gas attenuates embryonic gene expression and prevents left ventricular remodeling induced by intermittent hypoxia in cardiomyopathic hamsters.Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report.Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis.Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism.The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients.Cardiotoxicity with vascular endothelial growth factor inhibitor therapy Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms Tyrosine Kinase Inhibitor-Induced Acute Myocarditis, Myositis, and Cardiogenic Shock

P2860

Q26864094-C39F23FB-72A5-4C30-B30F-E501FEF6998A Q28551385-C3504190-5FE8-4122-B5FA-7CE3BC582018 Q34441749-814137D0-82A6-481D-B2B6-B7B46E2C5734 Q36819774-046CA90E-F899-42EB-9F7C-D4092C865D23 Q38580452-BBD3740D-4993-43BB-A183-7EFD420AB44E Q38693165-E69CB79C-2AD9-4267-A6A3-2A11D5A27B35 Q38797807-67D7494C-733C-4327-969B-A17924419913 Q41112375-E4F4240E-C2FD-47FC-A36D-585C99DB43D1 Q41167795-3FD224CD-A269-4202-8864-D214471F01AB Q42703995-BF528646-DC3A-47FB-9B69-C942C757445E Q42980163-A13347F6-5626-4D9D-8EA6-755CC74A2DB5 Q47681122-2DD54B29-B488-4F1A-B9D4-0672F21CFC51 Q47699276-5461FC7E-3F06-43A6-A0FD-A9156CA2C2B0 Q47871357-61672404-4E25-4AB9-B4F1-0321D87C7E76 Q52723478-B74710D2-0E00-42A3-8897-EA26DCD0B241 Q56991273-AD91281A-DD12-4E25-918C-03B79B1DA6B5 Q58554222-3509CFAC-1E34-4406-940A-A3F9E8F9B0FC Q58570996-AF0B70FB-6B08-4201-AF3E-1932446E57B1

P2860

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

http://www.wikidata.org/entity/Q33681995

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

@ast

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

@en

type

label

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

@ast

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

@en

prefLabel

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

@ast

Sorafenib cardiotoxicity increases mortality after myocardial infarction.

@en

P1433

Q33681995-8573F447-55C0-4F5E-AAA1-193BCC6F2458

P1476

Q33681995-C18B6AF3-B6DB-4695-98D6-F2D11D114FBD

P2093

Q33681995-0DB84D05-4855-472A-8EED-9B0D6C9648ED

Q33681995-17342ACD-1DC9-4385-801E-BAE40A2355ED

Q33681995-244BCD95-5E27-47F4-8DD6-030554624E4F

Q33681995-35F8277C-323D-4527-A1E9-7B30602FF6B4

Q33681995-386D1641-3278-4D6A-BC41-AFEFFD47A2BC

Q33681995-4C6C32C0-2429-4DAD-9BA3-D25B555AC11B

Q33681995-6FC57F67-C7C3-4080-B6DF-AD62FE22902C

Q33681995-72B1AA25-3322-45DF-8EB6-58B004A7AC43

Q33681995-80F03307-F196-41B0-A63F-B2C9BECC6C78

Q33681995-925F73B7-5F44-4FA5-9F87-0F7795723A7A

P2860

Q33681995-092EBAE1-548B-4E17-98CC-454286A190C5

Q33681995-0B2DED5D-451C-47A1-8A95-744856B4C5EC

Q33681995-0DC68599-7597-4E43-9D21-3A97B3C495BE

Q33681995-0EB2C40D-5190-4C46-BEDC-78A62F292141

Q33681995-111B5915-3C39-455F-926B-FD21FE6834C3

Q33681995-1489F857-0BAF-42FC-8DF0-81DA7C181CC1

Q33681995-19D86E2E-5127-4A1C-A606-DE1A4A15AD4D

Q33681995-19E339E6-CD4B-4749-B852-59840D219A66

Q33681995-242179F1-D83D-4ADD-93F1-F582D90B0B40

Q33681995-28F75CAA-1DD9-4FA7-97C0-ABF45AA60057

P304

Q33681995-5FB093E6-C61C-4C32-B30D-96F7C7FB89F7

P31

Q33681995-F73DA9A0-4E04-433A-8BA5-A3D19A8B6BE8

P356

Q33681995-13965743-6F42-41C8-8A3A-C995E869D71F

P433

Q33681995-3A4EE31E-9DCA-4EBD-AE8E-6A13192C140F

P478

Q33681995-AD9DB6F5-74DF-4B0F-B294-D5CA1CB450D1

P50

Q33681995-96D0292A-1107-4FCD-A314-5505E8214FF5

Q33681995-C97DE844-37D8-4269-987D-27D6D5519F80

Q33681995-E7E0B47E-3C3E-4286-9F9B-BD68FF951457

P577

Q33681995-E7B81E99-97FF-43FE-A89F-83CA90F8821A

P698

Q33681995-1011B167-C4F5-4C42-8DC0-F26EA54EA6E0

P932

Q33681995-0A178842-BEC8-4DB1-A161-5188BA69A5E0

P356

CIRCRESAHA.114.303200

P1433

Circulation Research

P1476

Sorafenib cardiotoxicity increases mortality after myocardial infarction

@en

P2093

Catherine A Makarewich

http://www.w3.org/2001/XMLSchema#string

Danielle Trappanese

http://www.w3.org/2001/XMLSchema#string

Daohai Yu

http://www.w3.org/2001/XMLSchema#string

Erhe Gao

http://www.w3.org/2001/XMLSchema#string

Hajime Kubo

http://www.w3.org/2001/XMLSchema#string

Jason M Duran

http://www.w3.org/2001/XMLSchema#string

Jonathan Dunn

http://www.w3.org/2001/XMLSchema#string

Polina Gross

http://www.w3.org/2001/XMLSchema#string

Remus M Berretta

http://www.w3.org/2001/XMLSchema#string

Ronald J Vagnozzi

http://www.w3.org/2001/XMLSchema#string

P2860

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib

Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension

CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme

Bone marrow cells regenerate infarcted myocardium

FLT-3: a new focus in the understanding of acute leukemia

Sorafenib in advanced clear-cell renal-cell carcinoma

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Targeting cancer with small molecule kinase inhibitors

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Adult cardiac stem cells are multipotent and support myocardial regeneration

P304

1700-1712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCRESAHA.114.303200

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24718482

http://www.w3.org/2001/XMLSchema#string

P932

4037647

http://www.w3.org/2001/XMLSchema#string